BioAscent

Executive Summary

BioAscent is a UK-based contract research organization (CRO) founded in 2013, providing integrated drug discovery services from target identification to preclinical candidate selection. Located in Newhouse, Scotland, the company offers medicinal and synthetic chemistry, computational chemistry, in vitro biosciences, DMPK, and compound management, supported by proprietary diversity and fragment libraries. As a private company with no disclosed funding, BioAscent has built a reputation for supporting pharma and biotech clients in small molecule discovery. The growing trend of pharmaceutical outsourcing positions the company for steady demand, though competition from larger CROs remains intense. With a focus on quality and breadth of services, BioAscent is well-placed to capture niche projects requiring integrated solutions.

Upcoming Catalysts (preview)

• Q3 2026Major pharma partnership or multi-year contract win70% success
• TBDExpansion of laboratory capacity or new service offering60% success
• TBDStrategic acquisition or investment from a larger CRO40% success